The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients

Inflamm Bowel Dis. 2024 Feb 1;30(2):318-319. doi: 10.1093/ibd/izad144.

Authors

Antonius T Otten¹, Gerard Dijkstra¹, Marijn C Visschedijk¹, Arno R Bourgonje^{1

2}

Affiliations

¹ Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
² The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

PMID: 37523671
DOI: 10.1093/ibd/izad144

No abstract available

Publication types

Editorial
Comment

MeSH terms

Drug Monitoring*
Humans
Inflammatory Bowel Diseases* / drug therapy
Infliximab / therapeutic use

Substances

Infliximab